Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.37
SPPI's Cash to Debt is ranked lower than
75% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. SPPI: 1.37 )
Ranked among companies with meaningful Cash to Debt only.
SPPI' s Cash to Debt Range Over the Past 10 Years
Min: 0.2  Med: 12.83 Max: 17918
Current: 1.37
0.2
17918
Equity to Asset 0.48
SPPI's Equity to Asset is ranked lower than
71% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SPPI: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
SPPI' s Equity to Asset Range Over the Past 10 Years
Min: 0.2  Med: 0.59 Max: 0.95
Current: 0.48
0.2
0.95
F-Score: 3
Z-Score: 0.12
M-Score: -3.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -24.01
SPPI's Operating margin (%) is ranked higher than
60% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. SPPI: -24.01 )
Ranked among companies with meaningful Operating margin (%) only.
SPPI' s Operating margin (%) Range Over the Past 10 Years
Min: -3452.69  Med: -67.85 Max: 30.17
Current: -24.01
-3452.69
30.17
Net-margin (%) -30.23
SPPI's Net-margin (%) is ranked higher than
58% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. SPPI: -30.23 )
Ranked among companies with meaningful Net-margin (%) only.
SPPI' s Net-margin (%) Range Over the Past 10 Years
Min: -3230.85  Med: -49.76 Max: 35.19
Current: -30.23
-3230.85
35.19
ROE (%) -20.84
SPPI's ROE (%) is ranked higher than
58% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. SPPI: -20.84 )
Ranked among companies with meaningful ROE (%) only.
SPPI' s ROE (%) Range Over the Past 10 Years
Min: -72  Med: -29.15 Max: 39.19
Current: -20.84
-72
39.19
ROA (%) -10.46
SPPI's ROA (%) is ranked higher than
65% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. SPPI: -10.46 )
Ranked among companies with meaningful ROA (%) only.
SPPI' s ROA (%) Range Over the Past 10 Years
Min: -61.52  Med: -13.89 Max: 23.98
Current: -10.46
-61.52
23.98
ROC (Joel Greenblatt) (%) -3042.08
SPPI's ROC (Joel Greenblatt) (%) is ranked lower than
75% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. SPPI: -3042.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SPPI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -5547.35  Med: -1954.97 Max: 3089.46
Current: -3042.08
-5547.35
3089.46
Revenue Growth (3Y)(%) -4.60
SPPI's Revenue Growth (3Y)(%) is ranked lower than
57% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. SPPI: -4.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SPPI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -3.00 Max: 211.9
Current: -4.6
0
211.9
» SPPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

SPPI Guru Trades in Q1 2015

Paul Tudor Jones 38,000 sh (New)
Jim Simons 1,391,217 sh (+460.97%)
» More
Q2 2015

SPPI Guru Trades in Q2 2015

Jim Simons 1,785,917 sh (+28.37%)
Paul Tudor Jones Sold Out
» More
Q3 2015

SPPI Guru Trades in Q3 2015

Paul Tudor Jones 30,458 sh (New)
Jim Simons 1,773,517 sh (-0.69%)
» More
Q4 2015

SPPI Guru Trades in Q4 2015

Jim Simons 2,591,319 sh (+46.11%)
» More
» Details

Insider Trades

Latest Guru Trades with SPPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 20.70
SPPI's Forward P/E is ranked lower than
62% of the 342 Companies
in the Global Biotechnology industry.

( Industry Median: 16.21 vs. SPPI: 20.70 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.45
SPPI's P/B is ranked higher than
77% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. SPPI: 1.45 )
Ranked among companies with meaningful P/B only.
SPPI' s P/B Range Over the Past 10 Years
Min: 0.63  Med: 2.10 Max: 5.23
Current: 1.45
0.63
5.23
P/S 1.82
SPPI's P/S is ranked higher than
90% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 9.03 vs. SPPI: 1.82 )
Ranked among companies with meaningful P/S only.
SPPI' s P/S Range Over the Past 10 Years
Min: 1.07  Med: 3.96 Max: 608
Current: 1.82
1.07
608
PFCF 12.18
SPPI's PFCF is ranked higher than
78% of the 266 Companies
in the Global Biotechnology industry.

( Industry Median: 30.10 vs. SPPI: 12.18 )
Ranked among companies with meaningful PFCF only.
SPPI' s PFCF Range Over the Past 10 Years
Min: 6.7  Med: 14.16 Max: 427
Current: 12.18
6.7
427
POCF 19.69
SPPI's POCF is ranked higher than
60% of the 392 Companies
in the Global Biotechnology industry.

( Industry Median: 27.83 vs. SPPI: 19.69 )
Ranked among companies with meaningful POCF only.
SPPI' s POCF Range Over the Past 10 Years
Min: 6.6  Med: 13.12 Max: 34.03
Current: 19.69
6.6
34.03
Current Ratio 2.05
SPPI's Current Ratio is ranked lower than
74% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. SPPI: 2.05 )
Ranked among companies with meaningful Current Ratio only.
SPPI' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.75 Max: 16.82
Current: 2.05
0.56
16.82
Quick Ratio 1.98
SPPI's Quick Ratio is ranked lower than
70% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. SPPI: 1.98 )
Ranked among companies with meaningful Quick Ratio only.
SPPI' s Quick Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.61 Max: 16.8
Current: 1.98
0.56
16.8
Days Inventory 108.80
SPPI's Days Inventory is ranked higher than
56% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. SPPI: 108.80 )
Ranked among companies with meaningful Days Inventory only.
SPPI' s Days Inventory Range Over the Past 10 Years
Min: 78.11  Med: 113.58 Max: 281.63
Current: 108.8
78.11
281.63
Days Sales Outstanding 107.11
SPPI's Days Sales Outstanding is ranked lower than
73% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. SPPI: 107.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
SPPI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 9.09  Med: 109.78 Max: 181.55
Current: 107.11
9.09
181.55
Days Payable 379.60
SPPI's Days Payable is ranked higher than
92% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. SPPI: 379.60 )
Ranked among companies with meaningful Days Payable only.
SPPI' s Days Payable Range Over the Past 10 Years
Min: 89.64  Med: 202.30 Max: 7902.06
Current: 379.6
89.64
7902.06

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.94
SPPI's Price/Projected FCF is ranked higher than
90% of the 273 Companies
in the Global Biotechnology industry.

( Industry Median: 2.91 vs. SPPI: 0.94 )
Ranked among companies with meaningful Price/Projected FCF only.
SPPI' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.19  Med: 1.74 Max: 9.32
Current: 0.94
1.19
9.32
Price/Median PS Value 0.45
SPPI's Price/Median PS Value is ranked higher than
81% of the 846 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. SPPI: 0.45 )
Ranked among companies with meaningful Price/Median PS Value only.
SPPI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.15  Med: 2.68 Max: 2656.25
Current: 0.45
0.15
2656.25
Price/Graham Number 3.16
SPPI's Price/Graham Number is ranked lower than
60% of the 431 Companies
in the Global Biotechnology industry.

( Industry Median: 2.37 vs. SPPI: 3.16 )
Ranked among companies with meaningful Price/Graham Number only.
SPPI' s Price/Graham Number Range Over the Past 10 Years
Min: 0.34  Med: 2.10 Max: 8.93
Current: 3.16
0.34
8.93
Earnings Yield (Greenblatt) (%) -14.76
SPPI's Earnings Yield (Greenblatt) (%) is ranked lower than
64% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. SPPI: -14.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SPPI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -15.6  Med: 11.65 Max: 2183.8
Current: -14.76
-15.6
2183.8

More Statistics

Revenue(Mil) $164
EPS $ -0.76
Beta0.34
Short Percentage of Float22.75%
52-Week Range $4.14 - 7.74
Shares Outstanding(Mil)67.34

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 140 98 92 129
EPS($) -0.59 -0.61 -0.72 -0.04
EPS without NRI($) -0.59 -0.61 -0.72 -0.04

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NTR.Germany,
Spectrum Pharmaceuticals Inc was incorporated in Colorado in December 1987 as Americus Funding Corporation and reincorporated in Delaware in June 1997. The Company changed its corporate name in August 1996 to NeoTherapeutics, Inc., and to Spectrum Pharmaceuticals, Inc in December 2002. The Company and its wholly-owned subsidiaries is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. The Company market four oncology drugs: FUSILEV injection, ZEVALIN injection, FOLOTYN injection, and MARQIBO injection. Its product portfolio consisting of both commercial stage and development stage products that address various cancer types. FUSILEV, a novel folate analog formulation and the pharmacologically active isomer (the levo-isomer) of the racemic compound, calcium leucovorin. FOLOTYN, a folate analogue metabolic inhibitor, was discovered by Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute and developed by Allos Therapeutics, Inc. ZEVALIN injection for intravenous use is a prescription medication that is part of a three step treatment regimen consisting of: two treatments of rituximab and one treatment of Yttrium-90 (Y-90) ZEVALIN. MARQIBO is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. The Company markets and sells its drugs through a direct sales force in the U.S., and through distributors in Europe and Japan. The Company competes with Astra Zeneca PLC, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Co., Novartis AG, Genentech, Inc. (Roche), Bristol-Myers Squibb Company, GlaxoSmithKline, Biogen-IDEC Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. (Astellas Pharma), Cephalon, Inc. (Teva Pharmaceuticals), Sanofi-Aventis, Inc., Pfizer, Inc., Genta Incorporated, Merck, Celgene Corporation, BiPar Sciences, Inc., Genzyme Corporation, Shire Pharmaceuticals, Abbott Laboratories, Poniard Pharmaceuticals, Inc., and Johnson & Johnson. The development, production and marketing of its proprietary and generic drug and biologic products are subject to regulation for safety, efficacy and quality by numerous governmental authorities in the U.S. and other countries.
» More Articles for SPPI

Headlines

Articles On GuruFocus.com
AT&T Will Benefit From DirecTV Acquistion Aug 14 2015 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
5 Stocks Exceeding Expectations In 2012 Mar 31 2012 
Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Weekly CFO Buys Highlight: CNYD, PRWT, ANCB, SPPI, SPAX Jan 30 2011 
Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 24 2011 
Weekly Top Insider Buys: NPBC, FUL, GAM, SHLM, SPPI Jan 23 2011 
Spectrum Pharmaceuticals Inc. (SPPI) CFO Brett L Scott buys 4,000 Shares Jan 21 2011 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
Spectrum (SPPI) Initiates Phase III Study on SPI-2012 Feb 01 2016
Spectrum Pharmaceuticals Begins Enrolling Patients in Registrational Trial of SPI-2012, a Novel,... Jan 29 2016
Spectrum Pharmaceuticals Begins Enrolling Patients in Registrational Trial of SPI-2012, a Novel,... Jan 29 2016
Biotechnology Stocks Technical Data -- Regulus Therapeutics, Progenics Pharma, Spectrum Pharma, and... Jan 12 2016
Spectrum Pharmaceuticals Signs a Strategic Partnership With Servier Canada Jan 11 2016
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 11 2016
Spectrum Pharmaceuticals Signs a Strategic Partnership With Servier Canada Jan 11 2016
Spectrum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : January 7,... Jan 07 2016
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 05 2016
Healthcare Sector Equities Under the Scanner -- Xenoport, Tetraphase Pharma, uniQure, and Spectrum... Dec 29 2015
Spectrum Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 22 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Spectrum Pharmaceuticals, Inc. of... Dec 18 2015
Pre-market Equity Watch on Biotechnology -- Agenus, Arrowhead Research, Spectrum Pharma, and... Dec 18 2015
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events Dec 16 2015
Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for... Dec 16 2015
Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for... Dec 16 2015
TheGrantLawFirm, PLLC Withdraws Action on Behalf of Spectrum Pharmaceuticals, Inc. Purchasers Dec 15 2015
INVESTOR ALERT: The Law Offices of Vincent Wong Remind Investors of Class Action Involving Spectrum... Dec 15 2015
Marqibo® Made Available to Acute Lymphoblastic Leukemia Patients Through Global myTomorrows... Dec 10 2015
INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Spectrum Pharmaceuticals, Inc. and... Dec 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK